Home | About Us | Contact Us  
   
 
BACK TO INDEX
 
 
DAWN AC Anticoagulation Software E-Newsletter
   November 2007 
  IN THIS ISSUE
 
 
  • Backing up your Data
  • Woman Dies after Medical Notes Lost
  • Dosing Protocol
  • Molecules with Anti-Clotting Properties Found

     

  •  

     

    Welcome to the November edition of the DAWN AC Anticoagulation Software E-Newsletter for 2007.

     

     
    Backing up Your Data - Are You Backing up Regularly?

    As most of you know, backing up your patient data is essential to protect it in the event of a system crash, power cut, etc where data can be lost. But do you know how often your data is being backed up, if at all?
     
    For Dawn AC version 7 users, backups can be scheduled to run automatically so that this is taken care of for you. However, you should periodically check that scheduled backups are still running and have not stopped if maintenance work or updates have been performed on the server. 

    If you would like any advice on how to set this up, or need any assistance with backing up data on any version of Dawn AC, then please contact us at
    support@4s-dawn.com or call us on 015395 63091 and we will be more than happy to help you.

     

    Woman dies in Hospital after Medical Notes Lost

    The BBC News reported recently that a woman died after medical staff stored important clinical notes on sticky notepaper and paper towels. In August 2005, 78 year old Patricia Prowse was admitted to hospital for a minor operation. Eight days later Mrs Prowse suffered from a stroke and was not given essential anti-clotting medication.

     

    The coroners verdict was logged as death by natural causes, but it was mentioned that errors had contributed to the womans death.

     

    An inquest revealed that Mrs Prowse had been taking warfarin prior to going into hospital, and was supposed to have been given several injections of Clexane after the operation, but only received one jab, due to confusion and missing medical notes.

     
    Mrs Prowse's granddaughter Kelly Day said that her family are disgusted, and commented, "People should be able to go into hospital for a minor operation and come out alive rather than dying like this".
     
    To view the full article, follow the link below:
     
     
    Dosing Protocol Following a Procedure

     

    Several customers have commented that it takes a long time to re-establish INR control once a patient has stopped warfarin for a procedure. Dr. Roger Rehr and Mary Camilli-Muhr from the Cardiology Associates of West Reading in the USA are Dawn AC users and use the following regimen successfully for bringing patients back into therapeutic range after a procedure:

     

    "On the evening of the procedure, the patient takes 1.5 times their "usual" warfarin dose for that day based on their regimen prior to holding warfarin for the procedure.  They then continue on their prior regimen thereafter, and an INR is checked in 1 week.

    Use of this protocol requires a specific review for each patient to confirm that it is appropriate for that particular patient, and of course there are well-recognized patient groups that are NOT appropriately managed by this protocol. These groups include but are not necessarily limited to patients with recent thromboembolism, prosthetic cardiac valve in place less than 6 months, Bjork-Shiley valve, or the presence of three risk factors for thromboembolism [as defined by the AHA/ACC to include atrial fibrillation, LV dysfunction, previous thromboembolism, hypercoagulable condition, mechanical prosthesis], or the presence of a mechanical mitral prosthesis plus one risk factor."

     

    This may be helpful guidance for some users who want to develop a protocol for post-procedure care. If you have any comments on the above or wish to provide any feedback or ideas, then please email us at syd@4s-dawn.com.

     

    Molecules With Anti-Clotting Properties Found
     
     

    Researchers at Virginia Commonwealth University have discovered a new mechanism to inhibit enzymes that play a big part in clotting disorders. This may lead to new therapies being developed to treat clots in places such as the lungs and leg.

     
    The study conducted by Umesh R. Desai, a professor at the VCU School of Pharmacy, reported on the development of three molecules that have anticoagulant properties. These molecules (called sulfated DHPs), are different from commonly used anticoagulants such as heparin and coumarins.
     
    The professor commented "The molecules we have designed may possess several advantages compared to currently available anticoagulation drugs. For example, new anti-clotting therapies may result in reduced hospital stays compared to currently available anticoagulation drugs".
     
    To view more of this article, follow the link below:
     
     
     
     
    Phone: +44 (0) 15395 63091